Translational Biomarker Strategy: Preclinical to Clinical
Why drugs that work in mice fail in trials: bridging preclinical-to-clinical biomarker discontinuity via species, sampling, and assay standardization.
Introduction: Why Doesn't the Preclinical-to-Clinical Gap Close?
"Drugs that worked in mice fail in clinical trials"—this is the greatest challenge in antifibrotic drug development. When failures are analyzed, biomarker discontinuity (Translational Discontinuity) is most frequently cited.
Specifically, three factors:
- Species differences: Expression patterns and kinetics differ between mouse and human (e.g., no CCL-18 ortholog in mice)
- Sampling differences: Preclinical evaluation centers on tissue; clinical on serum and imaging
- Assay non-standardization: Even for the same marker, different assays produce non-comparable absolute values
This article explains translational biomarker strategies to overcome these challenges, using examples from IPF serum biomarkers and non-invasive MASLD markers.
1. Three Classes of Translational Biomarkers
Biomarkers used in drug development are classified into three types by purpose:
| Class | Purpose | Examples | Role in Preclinical | Role in Clinical |
|---|---|---|---|---|
| Target Engagement | Is the drug binding its target? | Target phosphorylation, receptor occupancy | MOA validation | Proof of Mechanism |
| Pharmacodynamic (PD Marker) | Is the drug action occurring? | Downstream signaling, tissue remodeling markers | Dose-response | Dose optimization, POC |
| Disease / Outcome | Is the disease improving? | KL-6, MRE stiffness, FVC | Histology + physiology | Efficacy assessment |
Key principle: Measuring the same class of markers in parallel across preclinical and clinical is the key to improving success rates.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Species Differences: Mouse/Rat ↔ Human Mapping
Complete Correspondence
- Hydroxyproline (HYP): Absolute quantification of collagen deposition across species. Preclinical gold standard. However, application to clinical tissue biopsy is limited.
- α-SMA (ACTA2): Myofibroblast marker. Conserved across species. Measurable by IHC in both.
- Col1a1 / COL1A1: Measurable at mRNA/protein level in both species.
Partial Correspondence (Caution Required)
- KL-6 (MUC1): Covered by insurance in Japan only (not in the US/EU); detection in mice requires specific antibodies. BAL fluid measurement is standard.
- Pro-C3 / PRO-C3: Measurable in both species, but absolute values are not comparable between species. Evaluate by percent change.
- TIMP-1: Measurable in both species, but baseline variability is high and analysis must account for individual differences.
No or Difficult Correspondence
- CCL-18 / PARC: No ortholog in mice. Use CCL-2 (MCP-1), CCL-17 as substitutes.
- ELF score: Combination of human serum PIIINP, TIMP-1, and HA. The same formula cannot be used in mice, so each component is measured individually.
- MRE (MR Elastography): Widely used as non-invasive stiffness measurement in clinic, but rodent MRE requires dedicated equipment and is not widespread.
For a full catalog of fibrosis biomarkers, see the Comprehensive Guide to Fibrosis Biomarkers.
3. Sampling Strategy: Building a "Common Language" Between Preclinical and Clinical
BAL ↔ Bronchoalveolar Lavage
Clinical IPF trials may include BAL (bronchoalveolar lavage). Collecting BAL fluid in preclinical bleomycin models and measuring KL-6, SP-D, and MMP-7 enables direct comparison with clinical data.
Timing of Serum Collection
In preclinical, single-point collection at termination (e.g., Day 21 post-dose) is standard, while clinical uses longitudinal collection. Bridging this gap:
- Introduce longitudinal sampling in preclinical: Baseline, interim (Day 7, 14), termination (Day 21, 28)
- Mouse blood volume constraints: Adult mouse total blood volume is ~1.5 mL. Longitudinal sampling is limited to 100 µL × 3-4 times. Multiplex technologies like Luminex that enable multi-parameter measurement from small samples are useful.
- PK/PD co-measurement: Measure PK and PD at the same time points to build exposure-response relationships.
Translation of Tissue Biopsy
- Preclinical: Necropsy allows evaluation of all organs → histology-centered
- Clinical: Biopsy is invasive and thus limited → reliance on non-invasive imaging (MRE, FibroScan, HRCT) and serum markers
To bridge this gap, incorporating non-invasive imaging (micro-CT, small animal MRE) in preclinical and pre-establishing correlations between histopathology and non-invasive markers is important.
4. Assay Standardization: Absolute Values vs. Percent Change
Why Absolute Value Comparison Is Difficult
Even for the same "Pro-C3," absolute values differ between assay kits (Nordic Bioscience, Labcorp, etc.). Additionally, ELISA lot-to-lot variation and preprocessing differences (serum vs. plasma, freeze-thaw cycles) can cause up to 20-30% variability.
Recommended Approach: Three Principles
- Evaluate by percent change from baseline: Percent change is less affected by species, facility, or lot than absolute values.
- Same lab, same lot measurement: Batch-process preclinical and clinical samples with the same assay.
- Reference standard sharing: Use international reference sera (e.g., NIBSC).
Reference: FDA Biomarker Qualification Program
The FDA operates a Biomarker Qualification program for specific uses (e.g., predicting FVC decline in IPF). Qualified markers facilitate smoother discussions with regulatory authorities.
5. Disease-Specific Recommended Translational Panels
IPF / Pulmonary Fibrosis
| Marker | Preclinical (Mouse BAL/Serum) | Clinical (Human Serum) | Notes |
|---|---|---|---|
| KL-6 | ○ (BAL preferred) | ◎ (insurance coverage in Japan) | Details |
| SP-D | ○ | ○ | Caution with smoking effects |
| MMP-7 | ○ | ○ | EMT marker |
| Col1a1/HYP | ◎ (tissue) | △ (biopsy only) | Histology-centered |
MASH / Liver Fibrosis
| Marker | Preclinical (Mouse) | Clinical (Human) | Notes |
|---|---|---|---|
| Pro-C3 | ○ | ◎ | ECM turnover guide |
| ALT/AST | ○ | ◎ | Basic panel |
| MRE (liver stiffness) | △ (dedicated device needed) | ◎ | Non-invasive |
| Col1a1/HYP | ◎ (tissue) | △ | Gold standard |
CKD / Renal Fibrosis
| Marker | Preclinical (UUO model) | Clinical | Notes |
|---|---|---|---|
| KIM-1 | ◎ | ○ | Tubular injury |
| NGAL | ○ | ○ | AKI → CKD |
| eGFR | △ (SCr conversion) | ◎ | Primary clinical indicator |
| UACR | ○ | ◎ | Albuminuria |
6. Case Study: Nintedanib's Translation
Nintedanib is an instructive success case from preclinical to clinical.
- Preclinical: Reduction of tissue collagen (HYP), BAL TGF-β, and PDGF in bleomycin mouse model confirmed.
- Phase II (TOMORROW): KL-6 and MMP-7 changes tracked in patient serum. Dose-dependent reductions observed.
- Phase III (INPULSIS): Primary endpoint was FVC change. KL-6 and SP-D measured secondarily, consistent with FVC effects.
- Real-world (INBUILD): Indication expanded to progressive fibrosing ILD. Serum marker changes correlated with clinical outcomes.
The key point is that markers established in preclinical (BAL KL-6, MMP-7) were continuously measured in serum during clinical trials. This gave the translational narrative consistency.
7. Practical Recommendations for Experimental Design
A practical checklist to make preclinical studies translatable:
- Multi-timepoint sampling: Collect serum and urine longitudinally, not just at termination.
- Use of clinical assay kits: When possible, use the same kits in preclinical that will be used in clinical trials.
- Imaging integration: Micro-CT, small animal MRE, ultrasound elastography for non-invasive assessment.
- Tissue × Serum × Imaging triangulation: Don't rely on a single marker; confirm consistency across multiple modalities.
- Dose-response clarity: Test 3-4 doses rather than a single dose to inform human dose estimation.
- Translational team formation: Preclinical and clinical researchers co-design the protocol.
Conclusion
Avoiding failure in preclinical-to-clinical translation requires designing biomarker continuity from the start. Understanding species differences, adopting common sampling strategies, and standardizing assays—these painstaking efforts bridge animal model POC to clinical success.
As competition in fibrosis drug development intensifies, investing in translational biomarker strategy will become a key differentiator.
Related Articles
- Comprehensive Guide to Fibrosis Biomarkers
- Practical Guide to IPF Serum Biomarkers
- ECM Turnover Markers: Pro-C3, C3M, C6M
- Non-invasive Diagnostic Markers for MASLD/MASH
- Pitfalls of the Bleomycin Model
- Fibrosis Quantification Hub
References
- FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. 2016.
- Arrowsmith J. Trial watch: Phase II failures. Nat Rev Drug Discov. 2011;10(5):328-329. PMID: 21532551.
- Karsdal MA, Nielsen MJ, Sand JM, et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Assay Drug Dev Technol. 2013;11(2):70-92. PMID: 23046407.
- Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007;334(7586):197. PMID: 17175568.
- Mathai SK, Schwartz DA, Warg LA. Translational research in pulmonary fibrosis. Transl Res. 2019;209:1-13. PMID: 30768925.